Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $275,417.00 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 19,060 shares of the firm’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $14.45, for a total transaction of $275,417.00. Following the completion of the sale, the chief operating officer owned 451,540 shares of the company’s stock, valued at $6,524,753. This trade represents a 4.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

• On Monday, March 23rd, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.83, for a total transaction of $263,599.80.
• On Friday, March 20th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.37, for a total transaction of $254,832.20.
• On Wednesday, March 18th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.18, for a total value of $251,210.80.
• On Monday, March 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.41, for a total value of $255,594.60.
• On Wednesday, March 11th, Julie Rubinstein sold 141,583 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.29, for a total value of $1,881,638.07.
• On Friday, March 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $12.96, for a total value of $247,017.60.
• On Monday, March 9th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.79, for a total value of $457,617.39.
• On Tuesday, March 10th, Julie Rubinstein sold 19,460 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.68, for a total transaction of $285,672.80.
• On Tuesday, March 3rd, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.67, for a total transaction of $484,845.47.
• On Thursday, March 5th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $16.00, for a total transaction of $495,056.00.

Adaptive Biotechnologies Stock Performance

Shares of ADPT opened at $14.81 on Friday. Adaptive Biotechnologies Corporation has a twelve month low of $6.68 and a twelve month high of $20.76. The firm has a market capitalization of $2.28 billion, a P/E ratio of -37.02 and a beta of 2.29. The firm’s 50-day moving average is $15.45 and its two-hundred day moving average is $15.96.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The business had revenue of $71.68 million for the quarter, compared to analyst estimates of $59.38 million. During the same quarter in the previous year, the company earned ($0.23) EPS. The company’s quarterly revenue was up 51.0% on a year-over-year basis. Analysts predict that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several hedge funds have recently modified their holdings of the stock. Allianz Asset Management GmbH boosted its holdings in shares of Adaptive Biotechnologies by 305.8% in the 3rd quarter. Allianz Asset Management GmbH now owns 321,774 shares of the company’s stock valued at $4,814,000 after purchasing an additional 242,474 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of Adaptive Biotechnologies by 82.5% during the 3rd quarter. SG Americas Securities LLC now owns 68,113 shares of the company’s stock worth $1,019,000 after buying an additional 30,785 shares during the last quarter. Affinity Wealth Management LLC purchased a new position in shares of Adaptive Biotechnologies in the 3rd quarter worth $4,541,000. Aristotle Atlantic Partners LLC raised its position in shares of Adaptive Biotechnologies by 8.6% in the 3rd quarter. Aristotle Atlantic Partners LLC now owns 3,126,719 shares of the company’s stock worth $46,776,000 after buying an additional 247,402 shares during the period. Finally, Huntleigh Advisors Inc. acquired a new position in Adaptive Biotechnologies in the third quarter valued at $1,227,000. 99.17% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ADPT has been the subject of several recent research reports. Guggenheim raised their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a report on Monday, January 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. JPMorgan Chase & Co. upped their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Friday, February 6th. BTIG Research increased their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a report on Friday, February 6th. Finally, Wall Street Zen cut Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $18.25.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.